Ambrx Inc., a San-Diego based biotechnology company, has named Tiecheng (Alex) Qiao its CEO effective immediately.
Ambrx, a clinical stage company that discovers and develops optimized protein therapeutics known as bioconjugates, also has named Feng Tian as its chief science officer.
Qiao has more than 15 years of experience as an entrepreneur and senior manager in the life sciences, finance and technology industries.
The hires come on the heels of Ambrx entering a merger agreement with a Chinese consortium of entities providing the company with additional resources to advance the technology and product pipeline under development in its U.S. research center.
It will also allow Ambrx to build a new global product development center in China.